(Finance) – Lengthen your pace Johnson & Johnsonwhich trades with a modest advance of 1.51%.
Johnson & Johnson has entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion.
On a weekly basis, the stock’s trend is more solid than that of Dow Jones. At the moment, therefore, the appeal of investors is aimed more decisively at American multinational company that produces drugs and personal care products compared to the reference index.
The short-term scenario of Johnson & Johnson highlights a decline in prices towards the 142.9 USD area with the first resistance area seen at 144.9. Expectations are for a widening of the negative phase towards the support seen at 141.7.